Ameriprise
COGT icon

Ameriprise’s Cogent Biosciences COGT Stock Holding History

Ameriprise’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Buy
418,316
+166,202
+66% +$5.82M ﹤0.01% 1690
2026
Q1 		$9.7M Buy
252,114
+63,765
+34% +$2.35M ﹤0.01% 1952
2025
Q4 		$6.69M Buy
+188,349
New +$5.29M ﹤0.01% 2227
2025
Q2 		– Sell
-18,165
Closed -$109K – 3989
2025
Q1 		$109K Sell
18,165
-3,334
-16% -$26.1K ﹤0.01% 3870
2024
Q4 		$168K Buy
21,499
+9,459
+79% +$94.3K ﹤0.01% 3895
2024
Q3 		$130K Buy
12,040
+35
+0.3% +$341 ﹤0.01% 3806
2024
Q2 		$101K Buy
+12,005
New +$91.1K ﹤0.01% 3775

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise's COGT Position: Q2 2026 in Review

Ameriprise increased its Cogent Biosciences (COGT) stake by 66% in Q2 2026, buying an estimated $5.82M and bringing the position to 418,316 shares worth $16.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1690.

Ameriprise first reported a position in COGT in Q2 2024 and has held it in 7 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Ameriprise held 418,316 shares of Cogent Biosciences worth $16.2M as of Q2 2026.
  • Ameriprise bought 166,202 Cogent Biosciences shares in Q2 2026, an estimated $5.82M.
  • Cogent Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1690 holding.
  • Ameriprise first reported a position in Cogent Biosciences in Q2 2024 and has held it in 7 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.